(Q44249465)

1 December 2017

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus (English)

1 reference

1 December 2017

1 reference

M A van de Ree

1

1 reference

1 December 2017

M V Huisman

2

1 reference

1 December 2017

H M G Princen

3

1 reference

1 December 2017

A E Meinders

4

1 reference

1 December 2017

C Kluft

5

1 reference

1 December 2017

DALI-Study Group

6

1 reference

1 December 2017

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

166

1 reference

1 December 2017

1

1 reference

1 December 2017

129-135

1 reference

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Associations between change in C-reactive protein and serum lipids during statin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Statins and C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Serum neopterin in acute coronary syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in pri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

Elevated C-reactive protein levels in overweight and obese adults

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900316-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(02)00316-7

1 reference

1 December 2017

1 reference